Twice Yearly Treatment for the Control of LF

Status Completed

Clinical Trial Summary

The Global Program for the Elimination of Lymphatic Filariasis (GPELF) has been in operation sing the year 2000, with the aim of eliminating the disease by the year 2020, following 5-6 rounds of effective annual Mass Drug Administration (MDA). The treatment regimen is Ivermectin (IVM) in combination with Diethylcarbamazine (DEC) or Albendazole (ALB). In Ghana, MDA has been undertaken since 2001. While the disease has been eliminated in many areas, transmission has persisted in some implementation units that had experienced 15 or more rounds of MDA. Alternative intervention strategies, including twice yearly MDA and sleeping under insecticidal nets have significantly accelerated transmission interruption in some settings of high transmission intensity. Thus, it is evident that new intervention strategies could eliminate residual infection in areas of persistent transmission and speed up the LF elimination process. This study therefore seeks to test the hypothesis that biannual treatment of LF endemic communities will accelerate interruption of LF transmission.

Two cluster randomized trials will be implemented in LF endemic communities in Ghana. The interventions will be yearly or twice-yearly MDA delivered to entire endemic communities. Allocation to study group will be by clusters identified using the prevalence of LF. Clusters will be randomised to one of two groups: receiving either (1) annual treatment with IVM+ALB; (2) annual MDA with IVM +ALB, followed by an additional MDA 6 months later. The primary outcome measure is the prevalence of LF infection, assessed by four cross-sectional surveys. Entomological assessments will also be undertaken to evaluate the transmission intensity of the disease in the study clusters. Costs and cost-effectiveness will be evaluated. Among a random subsample of participants, microfilaria prevalence will be assessed longitudinally. A nested process evaluation, using semi-structured interviews, focus group discussions and a stakeholder analysis, will investigate the community acceptability, feasibility and scale-up of each delivery system.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03036059
Study type	Interventional
Source	Noguchi Memorial Institute for Medical Research
Contact
Status	Completed
Phase	Phase 4
Start date	May 19, 2017
Completion date	December 8, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00375583` - Effect of Albendazole Dose on Clearance of Filarial Worms	Phase 2
Completed	`NCT03664063` - PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs )	Phase 2
Recruiting	`NCT04844905` - Adjunctive Ivermectin Mass Drug Administration for Malaria Control	Phase 3
Completed	`NCT01975441` - Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa	Phase 2
Completed	`NCT01629771` - Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India	N/A
Completed	`NCT01905423` - Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis
Completed	`NCT02784743` - Impact of Albendazole -Ivermectin on Wuchereria Bancrofti in Mali	Phase 4
Completed	`NCT01905436` - Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia
Completed	`NCT02509481` - Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study	Phase 2/Phase 3
Completed	`NCT03268252` - Optimization of MDA With Existing Drug Regimens for LF: Monitoring Efficacy of Ongoing Treatment Programs in PNG
Completed	`NCT02927496` - A 24 Month Study, to Compare the Efficacy of Doxycycline vs. Placebo for Improving Filarial Lymphedema in Mali	Phase 3
Completed	`NCT02899936` - Death to Onchocerciasis and Lymphatic Filariasis (DOLF) Triple Drug Therapy for Lymphatic Filariasis	N/A
Completed	`NCT00511004` - Effect of Albendazole Dose on Treatment of Lymphatic Filariasis	Phase 2
Active, not recruiting	`NCT04258670` - Spontaneous Antigenemia in Loiasis
Completed	`NCT02974049` - Lymphatic Filariasis (LF) in Ivory Coast	N/A
Terminated	`NCT01213576` - Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi	N/A
Completed	`NCT02929121` - A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in India	Phase 3
Completed	`NCT00339417` - Effect of Albendazole Dose on Clearance of Filarial Worms	Phase 2
Withdrawn	`NCT01903057` - Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis	Phase 4
Completed	`NCT02032043` - Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast)